RVMD Revolution Medicines, Inc.
USHealthcareAs of 2026-10-08
Why RVMD matters now
Revolution Medicines, Inc. (RVMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $188.12 with -6.35% on the session and $39.99B in market capitalization; recent performance reads 1-month +10.65% and YTD +104.63%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-453.8M, and EPS of $-2.29. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.1%.
InvestLog's latest related AI research is a Insider Sale note titled "Kelsey Stephen Michael sells $18.7M of RVMD". The latest indexable market news headline is "Here Are Monday’s Top Wall Street Analyst Research Calls: Align Technology, AutoNation, Estee Lauder, Harley-Davidson, HubSpot, Microsoft, Mosaic, Ryder System, Wells Fargo & Company, and More" from 247 Wallst.
Additional event context on this page matters because analyst consensus is Buy with a median target of $177.00; recent insider activity includes Kelsey Stephen Michael filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
21.53
P/S
0.00
EV/EBITDA
-26.27
DCF Value
$0.88
FCF Yield
-3.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-83.2%
ROA
-60.9%
ROIC
-70.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-453.8M | $-2.29 |
| Q4 2025 | $0.00 | $-364.9M | $-1.90 |
| FY 2025 | $0.00 | $-1.13B | $-5.95 |
| Q3 2025 | $0.00 | $-305.2M | $-1.61 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$165.75
Target (Median)
$177.00
Target Range
$73.00 - $205.00
Trading Activity
Insider Trades
Related AI Research
Kelsey Stephen Michael sells $18.7M of RVMDKelsey Stephen Michael 内部减持 RVMD $18.7M
Kelsey Stephen Michael (Officer, See Remarks) sold 92,531 shares of Revolution Medicines, Inc. (RVMD) on 2026-09-11, at an average price of $202.36, for approximately $18.7M.Kelsey Stephen Michael（Officer, See Remarks）于 2026-09-11 卖出 Revolution Medicines, Inc.（RVMD）92,531 股，平均价格 $202.36，合计约 $18.7M。该交易于 2026-09-15 通过 SEC 原始 Form 4 披露。
Morgan Stanley initiates coverage of RVMD with OverweightMorgan Stanley 首次覆盖 RVMD，初始评级 增持（Overweight）
On 2026-09-10, Morgan Stanley initiated coverage of RVMD with a Overweight rating.Morgan Stanley 于 2026-09-10 首次覆盖 RVMD，初始评级为 增持（Overweight）。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.41
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.